Rhumbline Advisers Rallybio Corp Transaction History

Rhumbline Advisers

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 01, 2024	SELL	$1.34 - $2.98 $39,639 - $88,154	-29,582 Reduced 74.04%	10,372 $13,000
Q1 2024 May 09, 2024	BUY	$1.25 - $2.4 $1,493 - $2,868	1,195 Added 3.08%	39,954 $73,000
Q4 2023 Feb 08, 2024	SELL	$1.91 - $4.39 $19 - $43	-10 Reduced 0.03%	38,759 $92,000
Q3 2023 Nov 09, 2023	BUY	$3.37 - $6.16 $1,964 - $3,591	583 Added 1.53%	38,769 $130,000
Q2 2023 Aug 08, 2023	BUY	$4.31 - $8.89 $64,994 - $134,061	15,080 Added 65.26%	38,186 $216,000
Q1 2023 May 11, 2023	BUY	$4.37 - $8.75 $4,981 - $9,975	1,140 Added 5.19%	23,106 $132,000
Q4 2022 Feb 14, 2023	BUY	$4.67 - $14.86 $6,776 - $21,561	1,451 Added 7.07%	21,966 $144,000
Q3 2022 Nov 10, 2022	BUY	$7.54 - $14.56 $9,990 - $19,292	1,325 Added 6.9%	20,515 $297,000
Q2 2022 Aug 11, 2022	BUY	$6.26 - $13.65 $38,780 - $84,561	6,195 Added 47.67%	19,190 $145,000
Q1 2022 May 12, 2022	BUY	$6.91 - $15.04 $89,795 - $195,444	12,995 New	12,995 $91,000

31.9M

Ticker RLYB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,132,000
Market Cap $31.8M
Description
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of feta...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.